Latest in News & Research

Predictive Model Shows Moderate Performance for Psoriasis Relapse Risk

BMI, diabetes, biologic use, smoking, URTI, nonstandard medication were identified as independent risk factors and included in model

By Elana Gotkine (HealthDay News) | | May 13, 2026

Atopic Dermatitis Linked to Sleep, Memory Disturbances

Higher risk seen with increasing disease severity

By Lori Solomon (HealthDay News) | | May 13, 2026

Machine Learning Predicts Asthma Risk in Children With Early-Life Atopic Dermatitis

Models built based on routine electronic health record data

By Lori Solomon (HealthDay News) | | May 13, 2026

The Long View of Atopic Dermatitis Control

In treating atopic dermatitis, the question is not only how quickly a patient can improve, but how to build a plan that respects the...

| May 06, 2026

News Alert: Phase 3 ONWARD Trials Evaluate Envudeucitinib in Moderate to Severe Plaque Psoriasis

Findings presented at AAD26 highlight rapid onset and deepening responses through week 24 

By Dermsquared Editorial Team | | May 04, 2026

A Shift in Access for Actinic Keratosis

A late-March formulary update may change how often tirbanibulin is a realistic option in clinic.

By Dermsquared Editorial Team | | April 22, 2026

Maternal Prepregnancy BMI, Birth Length Linked to Offspring Atopic Dermatitis

Increasing birth length positively associated with atopic dermatitis by age 3 years, while inverse association seen for short birth length

By Elana Gotkine (HealthDay News) | | April 22, 2026

American Academy of Dermatology, March 27 to 31

The annual meeting of the American Academy of Dermatology was held from March 27 to 31 in Denver and attracted clinicians, academicians, allied health...

By HealthDay Physician's Briefing Staff | | April 22, 2026

Recommendations Developed for Prevention of Pediatric Atopic Dermatitis

Guidelines also developed for medical management of pediatric atopic dermatitis, including 27 evidence-based recommendations

By Elana Gotkine (HealthDay News) | | April 22, 2026

Mortality Varies With Primary Tumor Location in Cutaneous Melanoma

Increased mortality seen with primary tumor location in head and neck site; mortality reduced for location in upper limb/shoulder and lower limb/hip

By Dermsquared Editorial Team | | April 22, 2026

Consensus-Based Definitions Developed for Disease Activity in Atopic Dermatitis

Definitions developed for low disease activity, very low disease activity, remission in atopic dermatitis

By Dermsquared Editorial Team | | April 22, 2026

News Alert: Deucravacitinib Approved for Psoriatic Arthritis

An oral TYK2 inhibitor now carries an indication across both skin and joint disease

By Dermsquared Editorial Team | | April 17, 2026

What It Means to Treat Something That Doesn’t Behave Consistently

Atopic dermatitis rarely behaves the same way twice, which means the real work of treating it begins in everything we don’t immediately see.

| April 15, 2026

International Severity Criteria Developed for Vitiligo

Major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress

By Elana Gotkine (HealthDay News) | | April 09, 2026

AAD: Zasocitinib Safe, Effective for Moderate-to-Severe Plaque Psoriasis in Adults

Phase 3 studies show the highly selective oral tyrosine kinase 2 inhibitor provides rapid, durable skin improvement

By Lori Solomon (HealthDay News) | | April 09, 2026

AAD: Upadacitinib Safe, Effective for Nonsegmental Vitiligo

Benefits include total and facial repigmentation in patients 12 years and older versus placebo

By Lori Solomon (HealthDay News) | | April 09, 2026

AAD: Ixekizumab + Tirzepatide Boosts Psoriatic Arthritis Outcomes More Than Ixekizumab Monotherapy

Ixekizumab plus tirzepatide tied to simultaneous benefit of American College of Rheumatology 50 percent improvement and weight reduction

By Lori Solomon (HealthDay News) | | April 09, 2026

AAD: Subcutaneous Amlitelimab Aids Atopic Dermatitis Outcomes Through Week 24

Findings seen for skin clearance and disease severity with both every-four-week and every-12-week dosing

By Tina Brown (HealthDay News) | | April 09, 2026

Topical Melatonin Demonstrates Anti-Aging Effects in Human Skin

Topical melatonin improves hydration and firmness and reduces wrinkle depth and surface roughness in clinical studies

By Dermsquared Editorial Team | | April 09, 2026

AAD: AI-Based Medical Device Has High Accuracy for Skin Cancer

Sensitivity of DERM+ for identifying melanoma was 93.7 percent and for SCC, BCC was 100 and 99.2 percent

By Dermsquared Editorial Team | | April 09, 2026

No Link Found Between Childhood Atopic Dermatitis and Markers of Cardiovascular Risk

Authors say universal screening of all children with atopic dermatitis is unlikely to improve identification of early cardiovascular risk

By Lori Solomon (HealthDay News) | | April 09, 2026

Patients With Psoriasis Have Elevated Risk for Complications After Total Hip Arthroplasty

Higher superficial SSI, deep SSI, wound complications, sepsis, aseptic revision reported for those with cutaneous psoriasis

By Elana Gotkine (HealthDay News) | | April 09, 2026

AAD: Significant Benefits Seen for Brepocitinib 30 mg in Dermatomyositis

Mean Total Improvement Score significantly improved at week 52; brepocitinib was superior for all nine secondary outcomes

By Elana Gotkine (HealthDay News) | | April 09, 2026

24 of 1268